

Aryloxy and arylalkyleneoxy substituted imidazoquinolines**Publication number:** NZ545412 (A)**Publication date:** 2008-12-24**Inventor(s):** LINDSTROM KYLE J; MARTIN HUGUES; MERRILL BRYON A; RICE MICHAEL J; WURST JOSHUA R; HARALDSON CHAD A; KSHIRSAGAR TUSHAR; HEPPNER PHILIP D; NIWAS SHRI; GRIESGRABER GEORGE W; RADMER MATTHEW R +**Applicant(s):** COLEY PHARM GROUP INC +**Classification:****- international:** A61K31/4745; A61K31/5377; C07D413/14; C07D471/04; A61K31/4738; A61K31/5375; C07D413/00; C07D471/00; (IPC1-7): A61K31/4745**- European:** C07D471/04**Application number:** NZ20040545412 20040827**Priority number(s):** US20030498270P 20030827; US20040581254P 20040618; WO2004US28021 20040827**Also published as:**

- WO2005020999 (A1)
- US2009018122 (A1)
- RU2006105101 (A)
- MXPA06002199 (A)
- KR20070026298 (A)

[more >>](#)**Abstract of NZ 545412 (A)**

Disclosed are imidazoquinoline compounds of formula (II) with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, wherein the variables are defined in details in the specification, pharmaceutical compositions containing the compounds, intermediates thereof. These compounds are suitable as immunomodulators, for modulating cytokine biosynthesis in animals and may be used for the treatment of diseases including viral and neoplastic diseases, are disclosed.

.....
Data supplied from the *espacenet* database — Worldwide